Short-term results of a pulsed therapy with hydrocortisone eye drops to treat moderate to severe dry eye in primary Sjögren syndrome patients.
Dry eye disease
Hydrocortisone
Ocular Surface Disease Index
Sjögren syndrome
Tear film osmolarity
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
15
04
2022
accepted:
16
09
2022
revised:
03
09
2022
medline:
30
3
2023
pubmed:
4
10
2022
entrez:
3
10
2022
Statut:
ppublish
Résumé
We investigated the safety and efficacy of short-term treatment with topical low-dose hydrocortisone sodium phosphate 0.335% (PFH) in patients with moderate to severe primary Sjögren syndrome (SS)-related dry eye disease (DED). A retrospective single-centre interventional study. All patients received PFH for 6 days with a pulsed posology: three times daily for 2 days, twice daily for 2 days, and once daily for 2 days. This scheme was repeated for 3 consecutive months and then alternated for 3 months. Data were collected at baseline, 3 months, and 6 months of follow-up. A total of 40 SS patients were enrolled. Conjunctival hyperaemia and corneal-conjunctival stain significantly improved (p < 0.001). Ocular Surface Disease Index score reduced significantly between baseline and 3 months and between baseline and 6 months (p < 0.001). The tear film osmolarity lowered significantly in each eye from baseline to 3 months and from baseline to 6 months (p = 0.002 and p = 0.037, respectively). Comparing results at 3 and 6 months, the Ocular Surface Disease Index score (p = 1.000), the frequency of lacrimal substitutes installation (p = 0.632), and tear film osmolarity (right eye p = 0.518, left eye p = 1.000) did not change significantly. Intraocular pressure did not change during the study period. PFH eye drops with a pulsed posology improve signs and symptoms, not affecting the intraocular pressure in SS-related DED. Therefore, this pulsed treatment is safe and efficacious.
Sections du résumé
BACKGROUND
BACKGROUND
We investigated the safety and efficacy of short-term treatment with topical low-dose hydrocortisone sodium phosphate 0.335% (PFH) in patients with moderate to severe primary Sjögren syndrome (SS)-related dry eye disease (DED).
METHODS
METHODS
A retrospective single-centre interventional study. All patients received PFH for 6 days with a pulsed posology: three times daily for 2 days, twice daily for 2 days, and once daily for 2 days. This scheme was repeated for 3 consecutive months and then alternated for 3 months. Data were collected at baseline, 3 months, and 6 months of follow-up.
RESULTS
RESULTS
A total of 40 SS patients were enrolled. Conjunctival hyperaemia and corneal-conjunctival stain significantly improved (p < 0.001). Ocular Surface Disease Index score reduced significantly between baseline and 3 months and between baseline and 6 months (p < 0.001). The tear film osmolarity lowered significantly in each eye from baseline to 3 months and from baseline to 6 months (p = 0.002 and p = 0.037, respectively). Comparing results at 3 and 6 months, the Ocular Surface Disease Index score (p = 1.000), the frequency of lacrimal substitutes installation (p = 0.632), and tear film osmolarity (right eye p = 0.518, left eye p = 1.000) did not change significantly. Intraocular pressure did not change during the study period.
CONCLUSION
CONCLUSIONS
PFH eye drops with a pulsed posology improve signs and symptoms, not affecting the intraocular pressure in SS-related DED. Therefore, this pulsed treatment is safe and efficacious.
Identifiants
pubmed: 36192456
doi: 10.1007/s00417-022-05840-1
pii: 10.1007/s00417-022-05840-1
doi:
Substances chimiques
Ophthalmic Solutions
0
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1029-1036Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Jonsson R, Vogelsang P, Volchenkov R, Espinosa A, Wahren-Herlenius M, Appel S (2011) The complexity of Sjogren’s syndrome: novel aspects on pathogenesis. Immunol Lett 141:1–9. https://doi.org/10.1016/j.imlet.2011.06.007
doi: 10.1016/j.imlet.2011.06.007
pubmed: 21777618
Akpek EK, Bunya VY, Saldanha IJ (2019) Sjogren’s syndrome: more than just dry eye. Cornea 38:658–661. https://doi.org/10.1097/ICO.0000000000001865
doi: 10.1097/ICO.0000000000001865
pubmed: 30681523
pmcid: 6482458
Segal B, Bowman SJ, Fox PC, Vivino FB, Murukutla N, Brodscholl J, Ogale S, McLean L (2009) Primary Sjogren’s syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes 7:46. https://doi.org/10.1186/1477-7525-7-46
doi: 10.1186/1477-7525-7-46
pubmed: 19473510
pmcid: 2693523
Foulks GN, Forstot SL, Donshik PC, Forstot JZ, Goldstein MH, Lemp MA, Nelson JD, Nichols KK, Pflugfelder SC, Tanzer JM, Asbell P, Hammitt K, Jacobs DS (2015) Clinical guidelines for management of dry eye associated with Sjogren disease. Ocul Surf 13:118–132. https://doi.org/10.1016/j.jtos.2014.12.001
doi: 10.1016/j.jtos.2014.12.001
pubmed: 25881996
Adatia FA, Michaeli-Cohen A, Naor J, Caffery B, Bookman A, Slomovic A (2004) Correlation between corneal sensitivity, subjective dry eye symptoms and corneal staining in Sjogren’s syndrome. Can J Ophthalmol 39:767–771. https://doi.org/10.1016/s0008-4182(04)80071-1
doi: 10.1016/s0008-4182(04)80071-1
pubmed: 15696767
Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols JJ, Tsubota K, Stapleton F (2017) TFOS DEWS II definition and classification report. Ocul Surf 15:276–283. https://doi.org/10.1016/j.jtos.2017.05.008
doi: 10.1016/j.jtos.2017.05.008
pubmed: 28736335
Liu H, Begley C, Chen M, Bradley A, Bonanno J, McNamara NA, Nelson JD, Simpson T (2009) A link between tear instability and hyperosmolarity in dry eye. Invest Ophthalmol Vis Sci 50:3671–3679. https://doi.org/10.1167/iovs.08-2689
doi: 10.1167/iovs.08-2689
pubmed: 19324847
Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, Dong PN, Geerling G, Hida RY, Liu Y, Seo KY, Tauber J, Wakamatsu TH, Xu J, Wolffsohn JS, Craig JP (2017) TFOS DEWS II management and therapy report. Ocul Surf 15:575–628. https://doi.org/10.1016/j.jtos.2017.05.006
doi: 10.1016/j.jtos.2017.05.006
pubmed: 28736343
Sall K, Stevenson OD, Mundorf TK, Reis BL (2000) Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmol 107:631–639. https://doi.org/10.1016/s0161-6420(99)00176-1
doi: 10.1016/s0161-6420(99)00176-1
Razeghinejad MR, Katz LJ (2012) Steroid-induced iatrogenic glaucoma. Ophthalmic Res 47:66–80. https://doi.org/10.1159/000328630
doi: 10.1159/000328630
pubmed: 21757964
Kallab M, Szegedi S, Hommer N, Stegmann H, Kaya S, Werkmeister RM, Schmidl D, Schmetterer L, Garhofer G (2020) Topical low dose preservative-free hydrocortisone reduces signs and symptoms in patients with chronic dry eye: a randomized clinical trial. Adv Ther 37:329–341. https://doi.org/10.1007/s12325-019-01137-8
doi: 10.1007/s12325-019-01137-8
pubmed: 31741283
Carnahan MC, Goldstein DA (2000) Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 11:478–483. https://doi.org/10.1097/00055735-200012000-00016
doi: 10.1097/00055735-200012000-00016
pubmed: 11141645
McGhee CN, Dean S, Danesh-Meyer H (2002) Locally administered ocular corticosteroids: benefits and risks. Drug Saf 25:33–55. https://doi.org/10.2165/00002018-200225010-00004
doi: 10.2165/00002018-200225010-00004
pubmed: 11820911
Sheppard JD, Comstock TL, Cavet ME (2016) Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure. Adv Ther 33:532–552. https://doi.org/10.1007/s12325-016-0315-8
doi: 10.1007/s12325-016-0315-8
pubmed: 26984315
pmcid: 4846687
Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558. https://doi.org/10.1136/ard.61.6.554
doi: 10.1136/ard.61.6.554
pubmed: 12006334
pmcid: 1754137
(1991) Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 98: 741–756. https://doi.org/10.1016/s0161-6420(13)38009-9
Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, Gupta PK, Karpecki P, Lazreg S, Pult H, Sullivan BD, Tomlinson A, Tong L, Villani E, Yoon KC, Jones L, Craig JP (2017) TFOS DEWS II diagnostic methodology report. Ocul Surf 15:539–574. https://doi.org/10.1016/j.jtos.2017.05.001
doi: 10.1016/j.jtos.2017.05.001
pubmed: 28736342
Bron AJ, Evans VE, Smith JA (2003) Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 22:640–650. https://doi.org/10.1097/00003226-200310000-00008
doi: 10.1097/00003226-200310000-00008
pubmed: 14508260
Efron N (1998) Grading scales for contact lens complications. Ophthalmic Physiol Opt 18:182–186. https://doi.org/10.1016/s0275-5408(97)00066-5
doi: 10.1016/s0275-5408(97)00066-5
pubmed: 9692040
Pult H, Nichols JJ (2012) A review of meibography. Optom Vis Sci 89:E760-769. https://doi.org/10.1097/OPX.0b013e3182512ac1
doi: 10.1097/OPX.0b013e3182512ac1
pubmed: 22488268
Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL (2000) Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol 118:615–621. https://doi.org/10.1001/archopht.118.5.615
doi: 10.1001/archopht.118.5.615
pubmed: 10815152
Avunduk AM, Avunduk MC, Varnell ED, Kaufman HE (2003) The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol 136:593–602. https://doi.org/10.1016/s0002-9394(03)00326-x
doi: 10.1016/s0002-9394(03)00326-x
pubmed: 14516798
Pflugfelder SC, Maskin SL, Anderson B, Chodosh J, Holland EJ, De Paiva CS, Bartels SP, Micuda T, Proskin HM, Vogel R (2004) A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol 138:444–457. https://doi.org/10.1016/j.ajo.2004.04.052
doi: 10.1016/j.ajo.2004.04.052
pubmed: 15364229
Lin T, Gong L (2015) Topical fluorometholone treatment for ocular dryness in patients with Sjogren syndrome: a randomized clinical trial in China. Medicine (Baltimore) 94:e551. https://doi.org/10.1097/MD.0000000000000551
doi: 10.1097/MD.0000000000000551
pubmed: 25700323
Aragona P, Spinella R, Rania L, Postorino E, Sommario MS, Roszkowska AM, Puzzolo D (2013) Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sjogren syndrome. Eur J Ophthalmol 23:368–376. https://doi.org/10.5301/ejo.5000229
doi: 10.5301/ejo.5000229
pubmed: 23225089
Marsh P, Pflugfelder SC (1999) Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmol 106:811–816. https://doi.org/10.1016/S0161-6420(99)90171-9
doi: 10.1016/S0161-6420(99)90171-9
Pflugfelder SC (2004) Antiinflammatory therapy for dry eye. Am J Ophthalmol 137:337–342. https://doi.org/10.1016/j.ajo.2003.10.036
doi: 10.1016/j.ajo.2003.10.036
pubmed: 14962426
Rolando M, Vagge A (2017) Safety and efficacy of cortisol phosphate in hyaluronic acid vehicle in the treatment of dry eye in Sjogren syndrome. J Ocul Pharmacol Ther 33:383–390. https://doi.org/10.1089/jop.2016.0147
doi: 10.1089/jop.2016.0147
pubmed: 28375792
Hyon JY, Lee YJ, Yun PY (2007) Management of ocular surface inflammation in Sjogren syndrome. Cornea 26:S13-15. https://doi.org/10.1097/ICO.0b013e31812f6782
doi: 10.1097/ICO.0b013e31812f6782
pubmed: 17881909
Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, Knop E, Markoulli M, Ogawa Y, Perez V, Uchino Y, Yokoi N, Zoukhri D, Sullivan DA (2017) TFOS DEWS II pathophysiology report. Ocul Surf 15:438–510. https://doi.org/10.1016/j.jtos.2017.05.011
doi: 10.1016/j.jtos.2017.05.011
pubmed: 28736340